Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDCME: Practicing Precision in ALK and ROS1 Rearrangement Positive Non-Small Cell Lung Cancer (NSCLC): Testing, Targets, and Treatments

This one-credit activity features an expert panel providing their perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form